Palisade Bio (PALI) Capital Expenditures (2010 - 2022)
Palisade Bio (PALI) reported Capital Expenditures of $10000.0 for Q4 2022, up 900.0% on a QoQ basis from $1000.0 in Q4 2020.
Palisade Bio (PALI) has 10 years of Capital Expenditures data on file, last reported at $10000.0 in Q4 2022.
- Quarterly Capital Expenditures changed N/A year-over-year to $10000.0 in Q4 2022, while the trailing twelve-month figure through Sep 2024 was $10000.0 (changed 0.0% YoY) and the FY2023 annual result came in at $4000.0, down 60.0% from the prior year.
- Capital Expenditures grew to $10000.0 in Q4 2022 per PALI's latest filing, from $1000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $10000.0 in Q4 2022 and bottomed at -$1000.0 in Q3 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 10,000.00 |
| Dec 31, 2022 | 10,000.00 |
| Dec 31, 2020 | 1,000.00 |
| Dec 31, 2020 | 1,000.00 |
| Sep 30, 2020 | -1,000.00 |
| Sep 30, 2020 | -1,000.00 |
| Dec 31, 2017 | 408.00 |
| Dec 31, 2017 | 408.00 |
| Sep 30, 2017 | 1,319.00 |
| Sep 30, 2017 | 1,319.00 |
| Jun 30, 2016 | 83,490.00 |
| Jun 30, 2016 | 83,490.00 |
| Mar 31, 2016 | 14,598.00 |
| Mar 31, 2016 | 14,598.00 |
| Dec 31, 2015 | 48,059.00 |
| Dec 31, 2015 | 48,059.00 |
| Sep 30, 2015 | 32,194.00 |
| Sep 30, 2015 | 32,194.00 |
| Jun 30, 2015 | 79,967.00 |
| Jun 30, 2015 | 79,967.00 |
| Mar 31, 2015 | 16,052.00 |
| Mar 31, 2015 | 16,052.00 |
| Dec 31, 2014 | 35,722.00 |
| Dec 31, 2014 | 35,722.00 |
| Sep 30, 2014 | 27,080.00 |
| Sep 30, 2014 | 27,080.00 |
| Jun 30, 2014 | 34,004.00 |
| Jun 30, 2014 | 34,004.00 |
| Mar 31, 2014 | 111,087.00 |
| Mar 31, 2014 | 111,087.00 |
| Dec 31, 2013 | 6,424.00 |
| Dec 31, 2013 | 6,424.00 |
| Sep 30, 2013 | 113,546.00 |
| Sep 30, 2013 | 113,546.00 |
| Jun 30, 2013 | 3,736.00 |
| Jun 30, 2013 | 3,736.00 |
| Mar 31, 2013 | 1,656.00 |
| Mar 31, 2013 | 1,656.00 |
| Dec 31, 2012 | 9,017.00 |
| Dec 31, 2012 | 9,017.00 |
| Sep 30, 2012 | 593.00 |
| Sep 30, 2012 | 593.00 |
| Jun 30, 2012 | 29,610.00 |
| Jun 30, 2012 | 29,610.00 |
| Dec 31, 2011 | 9,320.00 |
| Dec 31, 2011 | 9,320.00 |
| Sep 30, 2011 | 5,132.00 |
| Sep 30, 2011 | 5,132.00 |
| Jun 30, 2011 | 131,791.00 |
| Jun 30, 2011 | 131,791.00 |
| Mar 31, 2011 | 50,169.00 |
| Mar 31, 2011 | 50,169.00 |
| Dec 31, 2010 | 48,341.00 |
| Dec 31, 2010 | 48,341.00 |
| Sep 30, 2010 | 1,590.00 |
| Sep 30, 2010 | 1,590.00 |